LNTH Quote, Financials, Valuation and Earnings

Electromed has a net margin of 34.61% compared to Lantheus Holdings's net margin of 10.05%. Lantheus Holdings's return on equity of 45.82% beat Electromed's return on equity of 15.62%.

Lantheus Holdings has a consensus price target of $134.69, signalling upside risk potential of 47.67%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 7.53%. Given that Lantheus Holdings has higher upside potential than Electromed, analysts believe Lantheus Holdings is more attractive than Electromed.

Lantheus Holdings has a beta of 0.459, which suggesting that the stock is 54.097% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $378.7M, which are larger than Electromed quarterly revenues of $14.7M. Lantheus Holdings's net income of $131.1M is higher than Electromed's net income of $1.5M. Notably, Lantheus Holdings's price-to-earnings ratio is 15.18x while Electromed's PE ratio is 42.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 4.33x versus 4.80x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Pulmonx has a net margin of 34.61% compared to Lantheus Holdings's net margin of -69.38%. Lantheus Holdings's return on equity of 45.82% beat Pulmonx's return on equity of -51.95%.

Lantheus Holdings has a consensus price target of $134.69, signalling upside risk potential of 47.67%. On the other hand Pulmonx has an analysts' consensus of -- which suggests that it could grow by 81.93%. Given that Pulmonx has higher upside potential than Lantheus Holdings, analysts believe Pulmonx is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.459, which suggesting that the stock is 54.097% less volatile than S&P 500. In comparison Pulmonx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulmonx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Pulmonx pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $378.7M, which are larger than Pulmonx quarterly revenues of $20.4M. Lantheus Holdings's net income of $131.1M is higher than Pulmonx's net income of -$14.1M. Notably, Lantheus Holdings's price-to-earnings ratio is 15.18x while Pulmonx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 4.33x versus 3.21x for Pulmonx. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of 34.61% compared to Lantheus Holdings's net margin of -35.93%. Lantheus Holdings's return on equity of 45.82% beat PROCEPT BioRobotics's return on equity of -37.42%.

Lantheus Holdings has a consensus price target of $134.69, signalling upside risk potential of 47.67%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 21.89%. Given that Lantheus Holdings has higher upside potential than PROCEPT BioRobotics, analysts believe Lantheus Holdings is more attractive than PROCEPT BioRobotics.

Lantheus Holdings has a beta of 0.459, which suggesting that the stock is 54.097% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $378.7M, which are larger than PROCEPT BioRobotics quarterly revenues of $58.4M. Lantheus Holdings's net income of $131.1M is higher than PROCEPT BioRobotics's net income of -$21M. Notably, Lantheus Holdings's price-to-earnings ratio is 15.18x while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 4.33x versus 21.65x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of 34.61% compared to Lantheus Holdings's net margin of -17.95%. Lantheus Holdings's return on equity of 45.82% beat RxSight's return on equity of -14.78%.

Lantheus Holdings has a consensus price target of $134.69, signalling upside risk potential of 47.67%. On the other hand RxSight has an analysts' consensus of -- which suggests that it could grow by 61.83%. Given that RxSight has higher upside potential than Lantheus Holdings, analysts believe RxSight is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.459, which suggesting that the stock is 54.097% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $378.7M, which are larger than RxSight quarterly revenues of $35.3M. Lantheus Holdings's net income of $131.1M is higher than RxSight's net income of -$6.3M. Notably, Lantheus Holdings's price-to-earnings ratio is 15.18x while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 4.33x versus 10.55x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.